Metronomic Chemotherapy for Breast Cancer
Oral Metronomic Cyclophosphamide with and without Methotrexate as Palliative Treatment for Patients with Metastatic Breast Carci
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
BreastCancerUpdate.com - Clinical Trials
JCM | Free Full-Text | Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2- Breast Cancer—A Retrospective Analysis of Consecutive Patients Data
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion | PLOS ONE
A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer - Clinical Breast Cancer
Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer
Metronomic chemotherapy in breast cancer | Semantic Scholar
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study - ScienceDirect
Achievements and challenges in the use of metronomics for the treatment of breast cancer - ScienceDirect
Metronomic vinorelbine (Navelbine) in patients with metastatic breast... | Download Scientific Diagram
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer | British Journal of Cancer
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients | Future Oncology
Frontiers | Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice
Cyclophosphamide | CancerIndex
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine
Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center - Lu - 2020 - Cancer Communications - Wiley Online Library
Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study | SpringerLink
Adjuvant metronomic chemotherapy in triple negative breast cancer | Download Table
Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus: Molecular Therapy
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor–Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 | Journal of Clinical Oncology
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion | PLOS ONE
